Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients. 2020

Camus Nimmo, and James Millard, and Kayleen Brien, and Sashen Moodley, and Lucy van Dorp, and Keeren Lutchminarain, and Allison Wolf, and Alison D Grant, and Francois Balloux, and Alexander S Pym, and Nesri Padayatchi, and Max O'Donnell
Division of Infection and Immunity, University College London, London, UK.

UI MeSH Term Description Entries
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D060085 Coinfection Simultaneous infection of a host organism by two or more pathogens. In virology, coinfection commonly refers to simultaneous infection of a single cell by two or more different viruses. Mixed Infection,Co-infection,Polymicrobial Infection,Secondary Infection,Secondary Infections,Co infection,Co-infections,Coinfections,Infection, Mixed,Infection, Polymicrobial,Infection, Secondary,Infections, Mixed,Infections, Polymicrobial,Infections, Secondary,Mixed Infections,Polymicrobial Infections
D018088 Tuberculosis, Multidrug-Resistant Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS. Tuberculosis, Drug-Resistant,Tuberculosis, MDR,Tuberculosis, Multi-Drug Resistant,Drug-Resistant Tuberculosis,MDR Tuberculosis,Multi-Drug Resistant Tuberculosis,Multidrug-Resistant Tuberculosis,Tuberculosis, Drug Resistant,Tuberculosis, Multi Drug Resistant,Tuberculosis, Multidrug Resistant
D064687 Diarylquinolines A class of quinoline compounds defined by the presence of two aromatic ring structures which are attached via a side chain to carbon 3 of the qunolinyl structure. The two aromatic moieties are typically NAPTHALENE and BENZENE. Several compounds in this class are used as ANTITUBERCULAR AGENTS. Diaryl Quinoline Derivative,Diarylquinoline,Diarylquinoline Derivative,Diaryl Quinoline Derivatives,Diarylquinoline Derivatives,Derivative, Diaryl Quinoline,Derivative, Diarylquinoline,Derivatives, Diaryl Quinoline,Derivatives, Diarylquinoline,Quinoline Derivative, Diaryl,Quinoline Derivatives, Diaryl

Related Publications

Camus Nimmo, and James Millard, and Kayleen Brien, and Sashen Moodley, and Lucy van Dorp, and Keeren Lutchminarain, and Allison Wolf, and Alison D Grant, and Francois Balloux, and Alexander S Pym, and Nesri Padayatchi, and Max O'Donnell
March 2019, The lancet. HIV,
Camus Nimmo, and James Millard, and Kayleen Brien, and Sashen Moodley, and Lucy van Dorp, and Keeren Lutchminarain, and Allison Wolf, and Alison D Grant, and Francois Balloux, and Alexander S Pym, and Nesri Padayatchi, and Max O'Donnell
December 2021, Infection & chemotherapy,
Camus Nimmo, and James Millard, and Kayleen Brien, and Sashen Moodley, and Lucy van Dorp, and Keeren Lutchminarain, and Allison Wolf, and Alison D Grant, and Francois Balloux, and Alexander S Pym, and Nesri Padayatchi, and Max O'Donnell
May 2007, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
Camus Nimmo, and James Millard, and Kayleen Brien, and Sashen Moodley, and Lucy van Dorp, and Keeren Lutchminarain, and Allison Wolf, and Alison D Grant, and Francois Balloux, and Alexander S Pym, and Nesri Padayatchi, and Max O'Donnell
February 1995, The New England journal of medicine,
Camus Nimmo, and James Millard, and Kayleen Brien, and Sashen Moodley, and Lucy van Dorp, and Keeren Lutchminarain, and Allison Wolf, and Alison D Grant, and Francois Balloux, and Alexander S Pym, and Nesri Padayatchi, and Max O'Donnell
January 2021, Frontiers in microbiology,
Camus Nimmo, and James Millard, and Kayleen Brien, and Sashen Moodley, and Lucy van Dorp, and Keeren Lutchminarain, and Allison Wolf, and Alison D Grant, and Francois Balloux, and Alexander S Pym, and Nesri Padayatchi, and Max O'Donnell
April 1991, Lancet (London, England),
Camus Nimmo, and James Millard, and Kayleen Brien, and Sashen Moodley, and Lucy van Dorp, and Keeren Lutchminarain, and Allison Wolf, and Alison D Grant, and Francois Balloux, and Alexander S Pym, and Nesri Padayatchi, and Max O'Donnell
January 2021, Le Mali medical,
Camus Nimmo, and James Millard, and Kayleen Brien, and Sashen Moodley, and Lucy van Dorp, and Keeren Lutchminarain, and Allison Wolf, and Alison D Grant, and Francois Balloux, and Alexander S Pym, and Nesri Padayatchi, and Max O'Donnell
March 2014, Public health action,
Camus Nimmo, and James Millard, and Kayleen Brien, and Sashen Moodley, and Lucy van Dorp, and Keeren Lutchminarain, and Allison Wolf, and Alison D Grant, and Francois Balloux, and Alexander S Pym, and Nesri Padayatchi, and Max O'Donnell
December 2017, Indian journal of microbiology,
Camus Nimmo, and James Millard, and Kayleen Brien, and Sashen Moodley, and Lucy van Dorp, and Keeren Lutchminarain, and Allison Wolf, and Alison D Grant, and Francois Balloux, and Alexander S Pym, and Nesri Padayatchi, and Max O'Donnell
April 2023, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia,
Copied contents to your clipboard!